Talha Badar, Hematology/Oncology specialist at Mayo Clinic, posted on X:
“Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress, New England Journal of Medicine.
With use of potent BCR: ABL1 directed TKI, long term survival outcome has significantly improved (>75%).
Important question from clinical standpoint : Is chemo-free (blinatumomab) induction with TKI is better than vs chemo +TKI?
Hopefully will be answered by EA9181 study: Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults.”
More posts featuring Talha Badar.